Disease Info Card

Extramedullary Hematopoiesis (disorder)

Information about Extramedullary Hematopoiesis (disorder): characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Extramedullary Hematopoiesis (disorder)

Most recent studies have shown that Extramedullary Hematopoiesis (disorder) shares some biological mechanisms with anemia, anemia-hemolytic, beta-thalassemia, compression-of-spinal-cord, fibrosis, hematological-disease, hemorrhage, hyperplasia, leukemia, lymphoma, malignant-neoplasms, malignant-paraganglionic-neoplasm, metaplasia, myeloid-leukemia, myeloproliferative-disease, neoplasms, polycythemia, polycythemia-vera, primary-myelofibrosis, thalassemia.

Among the many pathways, these few ones have gauged particular interests from scientists studying Extramedullary Hematopoiesis (disorder), and have been seen in publications frequently: Angiogenesis, Bone Resorption, Cell Death, Cell Development, Cell Differentiation, Cell Growth, Cell Proliferation, Coagulation, Hemopoiesis, Hypersensitivity, Immune Response, Lactation, Liver Development, Localization, Mating, Ossification, Pathogenesis, Phagocytosis, Regeneration, Secretion

Quite a number of genes have been found to play important roles in Extramedullary Hematopoiesis (disorder), such as CD34, CSF2, CSF3, CTLA4, EPO, EPX, GATA1, HLA-DQA1, IL3, IL6, JAK2, KITLG, NOD2, THPO, TIMP1, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.